2026-04-13T03:08:47Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/113932024-06-06T08:39:48Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Auclin, Edouard author Zubiri, Leyre author sophie, schneider author Minatta, Jose Nicolas author REMON, JORDI author Rodriguez-Abreu, Delvys author MUÑOZ COUSELO, EVA author 2024-04-30T09:24:56Z 2024-04-30T09:24:56Z 2024-04-22 Cancer; Immune checkpoint inhibitors; Solid-organ transplant Cáncer; Inhibidores de puntos de control inmunitario; Trasplante de órganos sólidos Càncer; Inhibidors de punts de control immunitari; Trasplantament d'òrgans sòlids Background Patients with solid organ transplant (SOT) and solid tumors are usually excluded from clinical trials testing immune checkpoint blockers (ICB). As transplant rates are increasing, we aimed to evaluate ICB outcomes in this population, with a special focus on lung cancer. Methods We conducted a multicenter retrospective cohort study collecting real data of ICB use in patients with SOT and solid tumors. Clinical data and treatment outcomes were assessed by using retrospective medical chart reviews in every participating center. Study endpoints were: overall response rate (ORR), 6-month progression-free survival (PFS), and grade ≥3 immune-related adverse events. Results From August 2016 to October 2022, 31 patients with SOT (98% kidney) and solid tumors were identified (36.0% lung cancer, 19.4% melanoma, 13.0% genitourinary cancer, 6.5% gastrointestinal cancer). Programmed death-ligand 1 expression was positive in 29% of tumors. Median age was 61 years, 69% were males, and 71% received ICB as first-line treatment. In the whole cohort the ORR was 45.2%, with a 6-month PFS of 56.8%. In the lung cancer cohort, the ORR was 45.5%, with a 6-month PFS of 32.7%, and median overall survival of 4.6 months. The grade 3 immune-related adverse events rate leading to ICB discontinuation was 12.9%. Allograft rejection rate was 25.8%, and risk of rejection was similar regardless of the type of ICB strategy (monotherapy or combination, 28% versus 33%, P = 1.0) or response to ICB treatment. Conclusions ICB could be considered a feasible option for SOT recipients with some advanced solid malignancies and no alternative therapeutic options. Due to the risk of allograft rejection, multidisciplinary teams should be involved before ICB therapy. http://hdl.handle.net/11351/11393 Càncer Immunosupressió Trasplantació d'òrgans, teixits, etc. Rebuig (Biologia) DISEASES::Neoplasms ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunosuppression PHENOMENA AND PROCESSES::Immune System Phenomena::Transplantation Immunology::Host vs Graft Reaction::Graft Rejection ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Transplantation::Organ Transplantation ENFERMEDADES::neoplasias TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunosupresión FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunología del trasplante::reacción huésped contra injerto::rechazo del injerto TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::trasplante::trasplante de órganos Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort